Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

NCT02369874 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02369874
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02369874 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
September 9, 2015
Completion date
November 13, 2020
Enrollment
736 (actual)
Sites
168

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent or metastatic pd-l1-positive or -negative squamous cell carcinoma of the head and neck scchn